

PUBLICATIONS 2023 BBE – Gustave Roussy

BUREAU DE BIOSTATISTIQUE ET D'EPIDEMIOLOGIE

BIOSTATISTICS AND EPIDEMIOLOGY DEPARTMENT

1. Roze S, Bertrand N, Eberst L, **Borget I.**
Projecting overall survival in health-economic models: uncertainty and maturity of data. *Current medical research and opinion*. 2023 Mar;39(3):367-374.
doi: 10.1080/03007995.2023.2167442. Epub 2023 Jan 23. PMID: 36628431
2. Debien V, Vignot S, Massard C, Malouf G, Hollebecque A, Scoazec J-Y, **Michiels S,** Verlingue L.
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.
Critical Reviews in Oncology / Hematology. 2023 Jan;181:103888.
doi: 10.1016/j.critrevonc.2022.103888. Epub 2022 Nov 29. PMID: 36460264
3. **Karamouza E,** Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X.
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
Cancers (Basel). 2023 Mar 17;15(6):1823. doi: 10.3390/cancers15061823.
PMID: 36980708; PMCID: PMC10047009.
4. Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, **Aupérin A,** Bourhis J.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Annals of Oncology. 2023 Jan;34(1):101-110.
doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. PMID: 36522816

5. Beishuizen A, Mellgren K, Andrés M, **Auperin A**, Bacon CM, Bomken S, Burke GAA, Burkhardt B, Brugieres L, Chiang AKS, Damm-Welk C, d'Amore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley MC, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu-Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner SD; European Intergroup for Childhood Non-Hodgkin Lymphoma. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. *The Lancet Haematology*. 2023 Mar;10(3):e213-e224. doi: 10.1016/S2352-3026(22)00374-X. PMID: 36858678
6. Mirghani H, Troux C, Leroy C, El Bedoui S, **Aupérin A**, Garic F, Bozec A, Schiappa R, Blanchard P, Gorphe P, Culié D. Post-therapeutic surveillance of HPV-driven oropharyngeal cancers: are we ready to change our practices ? *European Archives of Oto-Rhino-Laryngology*. 2023 Aug;280(8):3811-3820. doi: 10.1007/s00405-023-07952-8. Epub 2023 Apr 3. PMID: 37010600
7. Alexander S, **Aupérin A**, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke A, Zsiros J, Pillon M, Bollard CM, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas DA, Wheatley K, Patte C, Gross TG, Minard-Colin V; Children's Oncology Group; European Intergroup for Childhood Non-Hodgkin's Lymphoma. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. *The Lancet Haematology*. 2023 Jun;10(6):e445-e457. doi: 10.1016/S2352-3026(23)00062-5. Epub 2023 Apr 21. PMID: 37094596
8. Araujo D, Greystoke A, Bates S, **Bayle A**, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. *Annals of Oncology*. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. PMID: 36182023

9. Dare AJ, **Bayle A**, Hatoqai A, Mungo C, Velilla DG, Soto-Perez-de-Celis E, Gnangnon FHR, Lim MSH, Ralefala T, Mushininga VD.
Ensuring Global Access to Cancer Medicines: A Generational Call to Action. *Cancer Discovery*. 2023 Feb 6;13(2):269-274.
doi: 10.1158/2159-8290.CD-22-1372. PMID: 36734325
10. **Bayle A**, Belcaid L, Aldea M, Vasseur D, Peyraud F, Nicotra C, Geraud A, Sakkal M, Seknazi L, Cerbone L, Blanc-Durand F, Hadoux J, Mosele F, Tagliamento M, Bernard-Tessier A, Verret B, Smolenschi C, Clodion R, Auger N, Romano PM, Gazzah A, Camus MN, Micol J, Caron O, Hollebecque A, Lorient Y, Besse B, Lacroix L, Rouleau E, Ponce S, Soria JC, Barlesi F, Andre F, Italiano A.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. *Annals of Oncology*. 2023 Apr;34(4):389-396. doi: 10.1016/j.annonc.2023.01.008. Epub 2023 Jan 25. PMID: 36709039
11. Aldea M, Tagliamento M, **Bayle A**, Vasseur D, Vergé V, Marinello A, Danlos FX, Blanc-Durand F, Bernard E, Cerbone L, Mosele MF, Renneville A, Hadoux J, Lorient Y, Sakkal M, Vozy A, Sarkozy C, Smolenschi C, Nicotra C, Martin-Romano P, Boccon-Gibod C, Habza W, Lazarovici J, Ponce S, Hollebecque A, Marzac C, Lacroix L, Barlesi F, André F, Besse B, Rouleau E, Italiano A, Micol JB.
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. *JCO precision oncology*. 2023 Mar;7:e2200583. doi: 10.1200/PO.22.00583. PMID: 36862966
12. Benkirane H, Pradat Y, **Michiels S**, Cournède PH.
CustOmics: A versatile deep-learning based strategy for multi-omics integration. *PLoS Computational Biology*. 2023 Mar 6;19(3):e1010921.
doi: 10.1371/journal.pcbi.1010921. eCollection 2023 Mar. PMID: 36877736
13. Le Corroller A-G, **Bonastre J**.
Patient-reported measures: how useful in health economics?
The European Journal of Health Economics. 2023 Feb;24(1):1-4.
doi: 10.1007/s10198-022-01524-z. Epub 2022 Nov 8. PMID: 36346476
14. Bergerot CD, **Bonastre J**.
Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making. *European Urology Oncology*. 2023 Jun;6(3):349-350. doi: 10.1016/j.euo.2023.03.011. Epub 2023 Apr 7. PMID: 37032172

15. **Lueza B, Aupérin A**, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, **Bonastre J**.
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.
The European Journal of Health Economics. 2023 Apr 14.
doi: 10.1007/s10198-023-01581-y. Online ahead of print. PMID: 37058173
16. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Données et preuves en vie réelle dans l'évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? Therapie.
2023 Jan-Feb;78(1):66-80. doi: 10.1016/j.therap.2022.10.067.
Epub 2022 Oct 29. PMID: 36446648
17. Palmer S, **Borget I**, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J.
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. Value in Health. 2023 Feb;26(2):185-192.
doi: 10.1016/j.jval.2022.07.009. Epub 2022 Aug 13. PMID: 35970706
18. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? Therapie. 2023 Jan-Feb;78(1):81-94. doi: 10.1016/j.therap.2022.11.001.
Epub 2022 Nov 12. PMID: 36464522
19. Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, **Bouvier-Morel E**, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, **Borget I**.
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clinical cancer research. 2023 Jul 5;29(13):2401-2409.
doi: 10.1158/1078-0432.CCR-23-0046. PMID: 37074727

20. Veron L, **Chaltiel D**, Raynard B, Rassy N, Scotté F, Charles C, Pons M, De Jesus A, Accolas LG, Bergougnoux A, Caron O, Delalogue S.
Information needs on nutrition in link to cancer prevention among cancer patients, high-risk individuals and general population - A national cross-sectional study. *Clinical nutrition ESPEN*. 2023 Apr;54:421-429.
doi: 10.1016/j.clnesp.2023.02.018. Epub 2023 Feb 24. PMID: 36963889
21. Ogier du Terrail J, Leopold A, Joly C, Béguier C, Andreux M, Maussion C, Schmauch B, Tramel EW, Bendjebbar E, Zaslavskiy M, Wainrib G, Milder M, Gervasoni J, Guerin J, Durand T, Livartowski A, Moutet K, Gautier C, Djafar I, Moisson AL, Marini C, Galtier M, Balazard F, Dubois R, Moreira J, Simon A, **Drubay D**, Lacroix-Triki M, Franchet C, Bataillon G, Heudel PE.
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer. *Nature medicine*. 2023 Jan;29(1):135-146. doi: 10.1038/s41591-022-02155-w. Epub 2023 Jan 19. PMID: 36658418
22. Colomba E, **Jonas SF**, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, **Foulon S**, Fizazi K.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. *European Urology*. 2023 Jun 2;S0302-2838(23)02814-2.
doi: 10.1016/j.eururo.2023.05.009. Online ahead of print. PMID: 37271630
23. **Belhechmi S**, **Le Teuff G**, De Bin R, Rotolo F, **Michiels S**.
Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine. *BMC Bioinformatics*. 2023 Mar 16;24(1):96.
doi: 10.1186/s12859-023-05162-x. PMID: 36927444
24. Colomba E, Alexandre J, **Le Teuff G**, Genestie C, Coupez D, Coquard IR, Brachet PE, de Percin S, Sajous C, Fabbro M, Delanoy N, Joly F, Frenel JS, Pautier P, Leary A. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. *Gynecologic Oncology*. 2023 Feb;169:78-84.
doi: 10.1016/j.ygyno.2022.11.029. Epub 2022 Dec 13. PMID: 36521352

25. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**. Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. *The Lancet*. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. PMID: 37061269
26. Pradat Y, Viot J, Yurchenko AA, Gunbin K, Cerbone L, Deloger M, Grisay G, Verlingue L, Scott V, Padioleau I, Panunzi L, **Michiels S**, Hollebecque A, Jules-Clément G, Mezquita L, Lainé A, Loriot Y, Besse B, Friboulet L, André F, Cournède PH, Gautheret D, Nikolaev SI. Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. *Cancer Discovery*. 2023 May 4;13(5):1116-1143. doi: 10.1158/2159-8290.CD-22-0966. PMID: 36862804
27. Rahnenführer J, De Bin R, Benner A, Ambrogi F, Lusa L, Boulesteix AL, Migliavacca E, Binder H, **Michiels S**, Sauerbrei W, McShane L; for topic group "High-dimensional data" (TG9) of the STRATOS initiative. Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges. *BMC Medicine*. 2023 May 15;21(1):182. doi: 10.1186/s12916-023-02858-y. PMID: 37189125
28. Marmouset V, Morice PM, **Pagès A**, Leary A, Micol JB. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response. *Clinical Cancer Research*. 2023 Mar 14;29(6):1158-1159. doi: 10.1158/1078-0432.CCR-23-0164. PMID: 36916192
29. Franzoi MA, Degousée L, Martin E, Semedo PM, Aupomerol M, Soldato D, Di Meglio A, Chiodi C, Barbier A, Chaouachi H, Renvoisé N, Boinon D, Fasse L, Ribeiro J, Le-Provost JB, Arvis J, Lazorthes C, di Palma M, de Jesus A, Raynard B, **Pagès A**, Delalogue S, Pistilli B, Scotté F, Vaz-Luis I. Implementing a PROACTIVE Care Pathway to Empower and Support Survivors of Breast Cancer. *JCO Oncology Practice*. 2023 Jun;19(6):353-361. doi: 10.1200/OP.23.00016. PMID: 37307673

30. Petit C, Lee A, Ma J, **Lacas B**, Ng WT, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Tan T, Ngan RKC, Zhu G, Mai HQ, Hui EP, Fountzilias G, Zhang L, Carmel A, Kwong DLW, Moon J, Bourhis J, **Auperin A**, **Pignon JP**, Blanchard P; MAC-NPC Collaborative Group. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. *The Lancet Oncology*. 2023 Jun;24(6):611-623. doi: 10.1016/S1470-2045(23)00163-8. PMID: 37269842
31. Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, **Borget I**. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. *Thyroid*. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. PMID: 37350119
32. Farah L, Davaze-Schneider J, Martin T, Nguyen P, **Borget I**, Martelli N. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review. *Artificial Intelligence in Medicine*. 2023 Jun;140:102547. doi: 10.1016/j.artmed.2023.102547. Epub 2023 Apr 23. PMID: 37210155
33. Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, Ilies E, Zerdoud S, Sarini J, Zalzali M, La Manna L, Schneegans O, Kelly A, Kauffmann P, Rodien P, Brunaud L, Grunenwald S, Housseau E, Laghouati S, **Bouvet N**, Lecerf E, Hadoux J, Lamartina L, Schlumberger M, **Borget I**. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. *Trials*. 2023 Apr 28;24(1):298. doi: 10.1186/s13063-023-07294-0. PMID: 37118818
34. Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, Ilies E, Zerdoud S, Sarini J, Zalzali M, La Manna L, Schneegans O, Kelly A, Kaufmann P, Rodien P, Brunaud L, Grunenwald S, Housseau E, Laghouati S, **Bouvet N**, Lecerf E, Hadoux J, Lamartina L, Schlumberger M, **Borget I**. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. *Trials*. 2023 Jul 11;24(1):452. doi: 10.1186/s13063-023-07467-x. PMID: 37434205

35. Bayle A, **Bonastre J**, **Chaltiel D**, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R.
ESMO Study on the Availability and Accessibility of Biomolecular Technologies in Oncology in Europe. *Annals of Oncology*. 2023 Oct;34(10):934-945.
doi: 10.1016/j.annonc.2023.06.011. Epub 2023 Jul 3. PMID: 37406812
36. Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varenne AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, **Drubay D**, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L.
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. *Science*. 2023 Jun 9;380(6649):eabo2296.
doi: 10.1126/science.abo2296. Epub 2023 Jun 9. PMID: 37289890
37. Orlando V, **Drubay D**, Lavaud P, **Faivre L**, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Grosse-Goupil M, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Brihoum M, Culine S, **Teuff GL**, Fizazi K.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial. *Clinical Genitourinary Cancer*.
2023 Oct;21(5):615.e1-615.e8. doi: 10.1016/j.clgc.2023.05.003.
Epub 2023 May 7. PMID: 37263910
38. Brugières L, **Cozic N**, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, Bories P, Cottereau AS, Delmer A, Ducassou S, Garnier N, Lamant L, Leruste A, Millot F, Moalla S, Morschhauser F, Nolla M, Pagnier A, Reguerre Y, Renaud L, Schmitt A, Simonin M, Verschuur A, Hoog Labouret N, Mahier Ait Oukhatar C, Vassal G.
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial. *European Journal of Cancer*. 2023 Sep;191:112984.
doi: 10.1016/j.ejca.2023.112984. Epub 2023 Jul 17. PMID: 37549532

39. Faron M, **Cheugoua-Zanetsie M**, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Shapiro J, Vernerey D, Smithers BM, Walsh T, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, de Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Roth J, GebSKI V, Burmeister B, Paoletti X, van Sandick J, Fu J, **Pignon JP**, Ducreux M, **Michiels S**; MANATEC-02 Collaborative Group. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. *Journal of Clinical Oncology*. 2023 Oct 1;41(28):4535-4547. doi: 10.1200/JCO.22.02279. Epub 2023 Jul 12. PMID: 37467395
40. Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, **Karamouza E**, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. *European Journal of Cancer*. 2023 Sep;191:112966. doi: 10.1016/j.ejca.2023.112966. Epub 2023 Jul 4. PMID: 37542936
41. **Hill C**. Response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. *European Journal of Cancer*. 2023 Aug;189:112929. doi: 10.1016/j.ejca.2023.05.017. Epub 2023 Jun 14. PMID: 37327685
42. Mandima P, Baltrusaitis K, Montepiedra G, Aaron L, Mathad J, Onyango-Makumbi C, Nyati M, Ngocho J, Chareka G, Ponatshego P, Masheto G, McCarthy K, Jean-Philippe P, Gupta A, Stranix-Chibanda L; **IMPAACT P1078 T. B.** APPRISE study team. Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial. *BMC pregnancy and childbirth*. 2023 Jan 17;23(1):34. doi: 10.1186/s12884-022-05341-3. PMID: 36650479
43. Grumberg V, Chouaïd C, Gaudin AF, Le Tourneau C, Marabelle A, Bongiovanni-Delarozière I, Cotté FE, **Borget I**. Organizational Impact of Immunotherapies in Advanced Cancers in France. *JCO Global Oncology*. 2023 Aug;9:e2300026. doi: 10.1200/GO.23.00026. PMID: 37595168

44. Ashok Kumar P, **Karimi M**, Basnet A, Seymour L, Kratzke R, Brambilla E, Le-Chevalier T, Soria JC, Olaussen KA, Devarakonda S, Govindan R, Tsao MS, Shepherd FA, **Michiels S**, Graziano S.
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.
Clinical Lung Cancer. 2023 Sep;24(6):528-540.
doi: 10.1016/j.clcc.2023.06.002. Epub 2023 Jun 17. PMID: 37438216
45. Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, **Michiels S**, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papatomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Puzstai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, Van Der Laak J, Van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Mark Seaverns Barlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E.
Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
The Journal of Pathology. 2023 Aug;260(5):514-532. doi: 10.1002/path.6165. Epub 2023 Aug 23. PMID: 37608771

46. Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhusi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, **Michiels S**, Minhas FUA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, Van Der Laak J, Van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. *The Journal of Pathology*. 2023 Aug;260(5):498-513. doi: 10.1002/path.6155. Epub 2023 Aug 23. PMID: 37608772
47. Menssouri N, Poiraudreau L, Helissey C, Bigot L, Sabio J, Ibrahim T, Pobel C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Chauchereau A, Blanc-Durand F, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, van de Wiel P, den Biezen-Timmermans E, Wesseling-Rozendaal Y, Ponce-Aix S, **Michiels S**, Massard C, Gautheret D, Barlesi F, Andre F, Besse B, Scoazec JY, Friboulet L, Fizazi K, Loriot Y. Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors. *Clinical Cancer Research*. 2023 Nov 1;29(21):4504-4517. doi: 10.1158/1078-0432.CCR-22-3736. PMID: 37364000
48. Evrard E, Motamed C, **Pagès A**, Bordenave L. Opioid Reduced Anesthesia in Major Oncologic Cervicofacial Surgery: A Retrospective Study. *Journal of Clinical Medicine*. 2023 Jan 23;12(3):904. doi: 10.3390/jcm12030904. PMID: 36769551

49. Ram A, **Pagès A**, Cubilier E, Daoudi N, Vandergheynst F, Scotte F, Antoun S, Merad M.
COVID-19 impact on an oncologic emergency department visits: observational study. *BMJ Supportive & Palliative Care*. 2023 Feb 22;spcare-2023-004184.
doi: 10.1136/spcare-2023-004184. Online ahead of print. PMID: 36813536
50. Danlos FX, **Texier M**, Job B, Mouraud S, Cassard L, Baldini C, Varga A, Yurchenko AA, Rabeau A, Champiat S, Letourneur D, Bredel D, Susini S, Blum Y, Parpaleix A, Parlavecchio C, Tselikas L, Fahrner JE, Goubet AG, Rouanne M, Rafie S, Abbassi A, Kasraoui I, Breckler M, Farhane S, Ammari S, Laghouati S, Gazzah A, Lacroix L, Besse B, Droin N, Deloger M, Cotteret S, Adam J, Zitvogel L, Nikolaev SI, Chaput N, Massard C, Soria JC, Gomez-Roca C, Zalcman G, Planchard D, Marabelle A.
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. *Cancer Discovery*. 2023 Apr 3;13(4):858-879.
doi: 10.1158/2159-8290.CD-22-0886. PMID: 36669143
51. **Giudici F**, Pistilli B, Vaz-Luis I, **Karimi M**, Delalogue S, Bachelot T, **Michiels S**, **Bardet A**.
Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer. *British Journal of Cancer*. 2023 Oct;129(9):1516-1523.
doi: 10.1038/s41416-023-02420-w. Epub 2023 Sep 11. PMID: 37697030
52. **Karimi M**, Mendez-Pineda S, Blanché H, Boland A, Besse C, Deleuze J-F, Meng X-Y, Sirab N, Groussard K, Le Bret T, **Bonastre J**, Allory Y, Radvanyi F, Benhamou S, **Michiels S**.
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort. *Cancers*. 2023 Aug 23;15(17):4218.
doi: 10.3390/cancers15174218. PMID: 37686494
53. Herledan C, Toulemonde A, Clairet AL, Boulin M, Falandry C, Decker L, Rioufol C, **Bayle A**, Bertrand N.
Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO. *Critical Reviews in Oncology / Hematology*. 2023 Sep 1;190:104117. doi: 10.1016/j.critrevonc.2023.104117.
Online ahead of print. PMID: 37660933
54. Petit C, **Pignon J-P**, Blanchard P.
Incorporating absolute effects to enrich interpretation of findings from meta-analyses - Authors' reply. *The Lancet Oncology*. 2023 Sep;24(9):e359.
doi: 10.1016/S1470-2045(23)00402-3. PMID: 37657474

55. Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez Arango JD, Guaitoli G, Mizuta H, Combarel D, Tselikas L, **Michiels S**, Nikolaev SI, Scoazec JY, Ponce-Aix S, Besse B, Olaussen KA, Lorient Y, Friboulet L.
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. *Cancer Discovery*. 2023 Sep 6;13(9):1998-2011.
doi: 10.1158/2159-8290.CD-22-1441. PMID: 37377403
56. Rigault E, **Lacas B**, Glehen O, Smith D, Dupont-Bierre E, Guimbaud R, Malka D, Boige V, Fuerea A, **Pignon JP**, Ducreux M.
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment. *Cancer treatment and research communications*. 2023;34:100674. doi: 10.1016/j.ctarc.2022.100674. Epub 2022 Dec 16.
PMID: 36565566
57. Rassy E, Garberis I, Tran-Dien A, Job B, Chung-Scott V, Bouakka I, Bassil J, Ferkh R, Lacroix-Triki M, Zanconati F, **Giudici F**, Generali D, Rouleau E, Lacroix L, Andre F, Pistilli B.
Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers. *Clinical Cancer Research*. 2023 May 1;29(9):1822-1831.
doi: 10.1158/1078-0432.CCR-22-2883. PMID: 36805183
58. Pouget AM, Costa N, Mounié M, Gombault-Datzenko E, Derumeaux H, **Pagès A**, Rouzaud-Laborde C, Molinier L.
Mechanical Thrombectomy with Intravenous Thrombolysis versus Thrombolysis Alone for the Treatment of Stroke: a Systematic Review of Economic Evaluations. *Journal of Vascular and Interventional Radiology*. 2023 Oct;34(10):1749-1759.e2. doi: 10.1016/j.jvir.2023.06.015.
Epub 2023 Jun 17. PMID: 37331591
59. Georger B, **Paoletti X**, Bautista F, Gatz SA, Marshall LV, André N, Berlanga P, Ducassou S, Pasqualini C, Casanova M, Zwaan CM, Nysom K, Rubino J, Goff DV, **Archambaud B**, Abbou S, Schleiermacher G, Dufour C, Blanc P, Hoog-Labouret N, Buzyn A, Vassal G.
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial. *Nature Medicine*. 2023 Oct 19.
doi: 10.1038/s41591-023-02580-5. Online ahead of print. PMID: 37857712

60. Limkin E, Blanchard P, Lacas B, Bourhis J, Parmar M, Licitra L, Le QT, Yom SS, Fortpied C, Langendijk J, Vermorken JB, Bernier J, Overgaard J, Harris J, **Pignon JP**, **Auperin A**; MACH-NC* and MARCH** collaborative groups. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses. *Radiotherapy and oncology*. 2023 Nov 11;190:110011. doi: 10.1016/j.radonc.2023.110011. Online ahead of print. PMID: 37956890
61. Franzoi MA, **Bayle A**, Vaz-Luis I. Changing cancer representations toward comprehensive portraits to empower patients in their care journey. *Annals of oncology*. 2023 Dec;34(12):1082-1087. doi: 10.1016/j.annonc.2023.09.3117. Epub 2023 Oct 9. PMID: 37816461
62. Lemaitre F, Florentin V, Blin O, **Bayle A**, Benito S, Chauny JV, Galaup A, Korchagina D, Lang M, Le Tourneau C, Pelloux H, Picard N, Guilhaumou R. [Comment faire entrer la médecine de précision dans la décision thérapeutique de routine au lit du malade ?] [Article in French]. *Thérapie*. 2023 Nov 10:S0040-5957(23)00181-6. doi: 10.1016/j.therap.2023.10.014. Online ahead of print. PMID: 38129247
63. Bayle A, Marino P, Baffert S, Margier J, **Bonastre J**. [Cost of high-throughput sequencing (NGS) technologies: Literature review and insights]. [Article in French]. *Bulletin du cancer*. 2023 Oct 16:S0007-4551(23)00376-4. doi: 10.1016/j.bulcan.2023.08.013. Online ahead of print. PMID: 37852801
64. Lemaitre F, Florentin V, Blin O, **Bayle A**, Benito S, Chauny JV, Galaup A, Korchagina D, Lang M, Le Tourneau C, Pelloux H, Picard N, Guilhaumou R. Can precision medicine be integrated into routine therapeutic decisions at the bedside of patients? *Thérapie*. 2023 Dec 1:S0040-5957(23)00190-7. doi: 10.1016/j.therap.2023.11.007. Online ahead of print. PMID: 38065821
65. Lebret T, **Bonastre J**, **Fraslin A**, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Méjean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanché H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. *BMJ Open*. 2023 Dec 20;13(12):e075942. doi: 10.1136/bmjopen-2023-075942. PMID: 38128940

66. Jannin A, **Giudici F**, de la Fouchardière C, Al Ghuzlan A, Wassermann J, Chougnat CN, Drui D, Godbert Y, Ilouz F, Bardet S, Zanetta S, Roudaut N, Batisse Lignier M, Groussin L, Klein M, Zerdoud S, Lamartina L, Baudin E, Decaussin-Petrucci M, Leteurtre E, Borson Chazot F, Do Cao C, **Borget I**, Hadoux J; ENDOCAN-TUTHYREF Network.
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. *Thyroid*. 2023 Oct;33(10):1190-1200. doi: 10.1089/thy.2023.0164. PMID: 37855745
67. Martin T, Guercio A, Besseau H, Huot L, Guerre P, Atfeh J, Piazza L, Pineau J, Sabatier B, **Borget I**, Martelli N.
Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France. *International Journal of Technology Assessment in Health care*. 2023 Sep 21;39(1):e58. doi: 10.1017/S0266462323000521. PMID: 37732461
68. Bonvalot S, **Cozic N**, Le Cesne A, Blay JY, Penel N, Fau M, Chevreau C, Anract P, Waast D, Laurence V, Watson S, Duffaud F, Gouin F, Taieb S, Kind M, Lam L. ASO Visual Abstract: Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. *Annals of Surgical Oncology*. 2023 Dec;30(13):8671-8672. doi: 10.1245/s10434-023-14396-1. PMID: 37814181
69. Bonvalot S, **Cozic N**, Le Cesne A, Blay JY, Penel N, Fau M, Chevreau C, Anract P, Waast D, Laurence V, Watson S, Duffaud F, Gouin F, Taieb S, Kind M, Lam L. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. *Annals of Surgical Oncology*. 2023 Dec;30(13):8653-8659. doi: 10.1245/s10434-023-14341-2. Epub 2023 Sep 30. PMID: 37777684
70. Audinot B, **Drubay D**, Gaspar N, Mohr A, Cordero C, Marec-Bérard P, Lervat C, Piperno-Neumann S, Jimenez M, Mansuy L, Castex MP, Revon-Riviere G, Marie-Cardine A, Berger C, Piguet C, Massau K, Job B, Moquin-Beaudry G, Le Deley MC, Tabone MD, Berlanga P, Brugières L, D Crompton B, Marchais A, Abbou S. ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial. *Annals of oncology*. 2023 Dec 22:S0923-7534(23)05113-X. doi: 10.1016/j.annonc.2023.12.006. Online ahead of print. PMID: 38142939
71. **Hill C**.
[Trends in the frequency of cancer in France]. [Article in French]. *Bulletin du Cancer*. 2023 Oct 17:S0007-4551(23)00386-7. doi: 10.1016/j.bulcan.2023.09.007. Online ahead of print. PMID: 37858423

72. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG).**
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. *Lancet*.
2023 Nov 25;402(10416):1991-2003. doi: 10.1016/S0140-6736(23)01082-6.
Epub 2023 Nov 3. PMID: 37931633
73. Charles C, **Bardet A, Ibrahimi N,** Aromatario O, Cambon L, Imbert A, Pons M, Raynard B, Sauveplane D, Pouchepadass C, Baudinet C, Lambotte O, Marabelle A, Dauchy S.
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIME-FEAS feasibility study. *Journal of Telemedicine and Telecare*.
2023 Oct;29(9):716-724. doi: 10.1177/1357633X211021743.
Epub 2021 Jun 17. PMID: 34137641
74. Bruschi M, Midjek L, Ajilil Y, Vairy S, Lancien M, Ghermaoui S, Kergrohen T, Verreault M, Idbah A, de Biagi CAO Jr, Liu I, Filbin MG, Beccaria K, Blauwblomme T, Puget S, Tauziede-Espariat A, Varlet P, Dangouloff-Ros V, Boddaert N, **Le Teuff G,** Grill J, Montagnac G, Elkhatib N, Debily MA, Castel D.
Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling. *Neuro-oncology*. 2023 Sep 13:noad161.
doi: 10.1093/neuonc/noad161. Online ahead of print. PMID: 37702430
75. Chapelle C, **Le Teuff G,** Zufferey PJ, Laporte S, Ollier E.
A framework to characterise the reproducibility of meta-analysis results with its application to direct oral anticoagulants in the acute treatment of venous thromboembolism. *Research synthesis methods*. 2023 Oct 17.
doi: 10.1002/jrsm.1676. Online ahead of print. PMID: 37846195
76. Sarian G, Chalas C, **Le Teuff G,** Fayeche C, Dumas A, Demoor-Goldschmidt C, Fresneau B.
Post-treatment sperm cryopreservation practices in childhood and young adult cancer survivors. *Reproductive Biomedicine Online*. 2023 Oct 2;48(2):103573.
doi: 10.1016/j.rbmo.2023.103573. Online ahead of print. PMID: 38113762
77. Ben-Ammar I, Rousseau A, Nicolle R, Tarabay A, Boige V, Valery M, Pudlarz T, Malka D, Gelli M, Fernandez-De-Sevilla E, Fuerea A, **Tanguy ML,** Rouleau E, Barbe R, Mathieu JRR, Jaulin F, Smolenschi C, Hollebecque A, Ducreux M, Boileve A.
Precision medicine for KRAS wild-type pancreatic adenocarcinomas. *European Journal of Cancer*. 2023 Dec 15:197:113497.
doi: 10.1016/j.ejca.2023.113497. Online ahead of print. PMID: 38134480

78. Postel-Vinay S, Coves J, **Texier M**, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. *British Journal of Cancer*. 2023 Dec 14. doi: 10.1038/s41416-023-02514-5. Online ahead of print. PMID: 38097741
79. Tran BT, Gelin A, Durand S, **Texier M**, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C. Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. *Oncoimmunology*. 2022 Dec 17;12(1):2150472. doi: 10.1080/2162402X.2022.2150472. eCollection 2023. PMID: 36545254
80. **Hill C**. Baclofène dans le mésusage de l'alcool : quel rapport bénéfices/risques ? *La Revue du Praticien*. 6 Oct 2023.
81. **Hill C**. Épidémiologie du Covid : qu'avons-nous appris ? *La Revue du Praticien*. 20 Oct 2023.
82. **Hill C**. Risque de leucémie aiguë à proximité des vignobles : faut-il vraiment s'alarmer ? *La Revue du Praticien*. 26 Oct 2023.
83. Kasiri H, Ghazaiean M, Rouhani N, Naderi-Behdani F, Ghazaeian M, **Ghodssi-Ghassemabadi R**. The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial. *Journal of Investigative Medicine*. 2023 Feb;71(2):124-131. doi: 10.1177/10815589221141815. Epub 2023 Jan 16. PMID: 36647298
84. Arjmand B, Dehghanbanadaki H, Yoosefi M, Rezaei N, Mohammadi Fateh S, **Ghodssi-Ghassemabadi R**, Najjar N, Hosseinkhani S, Tayanloo-Beik A, Adibi H, Farzadfar F, Larijani B, Razi F. Association of plasma acylcarnitines and amino acids with hypertension: A nationwide metabolomics study. *PloS One*. 2023 Jan 17;18(1):e0279835. doi: 10.1371/journal.pone.0279835. eCollection 2023. PMID: 36649284

85. Hasani-Ranjbar S, Razmandeh R, **Ghodssi-Ghassemabadi R**, Khodabakhshi M, Ebrahimpour M.
Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients. *Iranian Journal of Public Health*.
2023 Feb;52(2):420-426. doi: 10.18502/ijph.v52i2.11895. PMID: 37089142
86. Taghizadeh H, Emamgholipour S, Hosseinkhani S, Arjmand B, Rezaei N, Dilmaghani-Marand A, Ghasemi E, Panahi N, Dehghanbanadaki H, **Ghodssi-Ghassemabadi R**, Najjar N, Asadi M, Khoshniat M, Larijani B, Razi F.
The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016. *Frontiers in endocrinology*. 2023 Feb 27;14:1058952.
doi: 10.3389/fendo.2023.1058952. eCollection 2023. PMID: 36923214
87. Rihab B, El Houari L, **Simon-Tillaux N**, Jean S, Marjolaine G.
The experience of dry mouth and screening for Sjogren's syndrome by the dentist: patient-reported experiences. *BMC Oral Health*.
2023 Dec 15;23(1):1010. doi: 10.1186/s12903-023-03727-z. PMID: 38102574
88. Massol J, **Simon-Tillaux N**, Tohme J, Hariri G, Dureau P, Duceau B, Belin L, Hajage D, De Rycke Y, Charfeddine A, Lebreton G, Combes A, Bouglé A.
Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data. *Critical Care*. 2023 Feb 7;27(1):51. doi: 10.1186/s13054-023-04328-6.
PMID: 36750852
89. Christiaens A, **Simon-Tillaux N**, Thompson W, Sinclair AJ, Henrard S, Boland BB, Slaouti-Jégou Y, Lekens B, Bonnet-Zamponi D, Tubach F, Zerah L.
Impact of deintensifying hypoglycaemic drugs in older adults with type 2 diabetes: protocol for an emulation of a target trial. *BMJ Open*.
2023 Nov 19;13(11):e073081. doi: 10.1136/bmjopen-2023-073081.
PMID: 37984943
90. Kedra J, Dieudé P, Giboin C, Marotte H, Salliot C, Schaefferbeke T, Perdriger A, Soubrier M, Morel J, Constantin A, Dernis E, Royant V, Salmon JH, Pham T, Gottenberg JE, Pertuiset E, Dougados M, Devauchelle-Pensec V, Gaudin P, Cormier G, Goupille P, Mariette X, Berenbaum F, Alcaix D, Rouidi SA, Berthelot JM, Monnier A, Piroth C, Lioté F, Goëb V, Gaujoux-Viala C, Chary-Valckenaere I, Hajage D, Tubach F, Fautrel B; **CRI-IMIDIATE clinical research network**.
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission. *Arthritis & rheumatology*. 2023 Nov 9. doi: 10.1002/art.42752.
Online ahead of print. PMID: 37942714

91. Del Baldo G, Vennarini S, Toniutti M, **Abbas R**, Lorentini S, Piccirilli E, Cacchione A, Megaro G, Di Ruscio V, De Loris MA, De Salvo A, Albino G, Rossi S, Colafati GS, Carai A, Mastronuzzi A.
Unraveling the impact of upfront chemotherapy and proton beam therapy on treatment outcome and follow-up in central nervous system germ cell tumors: a single center experience. *Frontiers in Oncology*. 2023 Oct 4:13:1259403.
doi: 10.3389/fonc.2023.1259403. eCollection 2023. PMID: 37860194
92. Malka D, Verret B, Faron M, Guimbaud R, Caramella C, Edeline J, Galais MP, Bengrine-Lefevre L, Smith D, Dupont-Bierre E, De Baere T, Goéré D, Dartigues P, Lacroix L, Boige V, Gelli M, **Pignon JP**, Ducreux M.
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial. *European Journal of Cancer*. 2023 Dec:195:113400.
doi: 10.1016/j.ejca.2023.113400. Epub 2023 Oct 28. PMID: 37922632
93. Gatz SA, Harttrampf AC, **Brard C**, Bautista F, Andre N, Abbou S, Rubino J, Rondof W, Deloger M, Rübsam M, Marshall LV, Hubschmann D, **Nebchi S**, Aerts I, Thebaud E, De Carli E, Defachelles AS, Paoletti X, Godin R, Miah K, Mortimer PGS, Vassal G, Geoerger B.
Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART trial. *Clinical Cancer Research*. 2023 Dec 5.
doi: 10.1158/1078-0432.CCR-23-2959. Online ahead of print. PMID: 38051741
94. Feltri G, Valenti G, Isidoro E, Kaur J, Treleani M, Bartelloni A, Mauro C, Spiga F, Ticich G, Di Napoli M, Biagi C, Pachetti M, Centonze S, Castriciano S, Zanchiello S, **Giudici F**, Gerin D, Zanconati F.
Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy. *European Journal of Medical Research*. 2023 Dec 11;28(1):582.
doi: 10.1186/s40001-023-01263-8. PMID: 38072937
95. Bernardi S, Taccogna S, D'Angelo M, **Giudici F**, Mauri G, Raggiunti B, Tina D, Zanconati F, Papini E, Negro R.
Immunocytochemistry Profile of Benign Thyroid Nodules Not Responding to Thermal Ablation: A Retrospective Study.
International Journal of Endocrinology. 2023 Apr 11:2023:7951942.
doi: 10.1155/2023/7951942. eCollection 2023. PMID: 37082757

96. Jenei K, Raymakers AJN, **Bayle A**, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. *The Lancet Oncology*. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4. PMID: 37269843

97. Moya-Plana A, Ngo C, **Lanoy E**, Vagner S, Robert C. eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma. *European Journal of Cancer*. 2023 May;184:120-123. doi: 10.1016/j.ejca.2023.01.032. Epub 2023 Feb 16.